Treatment status
| Status . | Low risk (n = 2) . | High risk (n = 32) . | Total (n = 34) . | |||
|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | No. . | % . | |
| Treatment completed per protocol | 2 | 100 | 21 | 66 | 23 | 68 |
| Disease progression | 0 | 3 | 9 | 3 | 9 | |
| Early termination | ||||||
| Adverse event | 0 | 5 | 16 | 5 | 15 | |
| Patient withdrawal | 0 | 1 | 3 | 1 | 3 | |
| Counts did not recover within time frame to begin cycle 4 | 0 | 1 | 3 | 1 | 3 | |
| Other complicating disease | 1 | 3 | 1 | 3 | ||
| Status . | Low risk (n = 2) . | High risk (n = 32) . | Total (n = 34) . | |||
|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | No. . | % . | |
| Treatment completed per protocol | 2 | 100 | 21 | 66 | 23 | 68 |
| Disease progression | 0 | 3 | 9 | 3 | 9 | |
| Early termination | ||||||
| Adverse event | 0 | 5 | 16 | 5 | 15 | |
| Patient withdrawal | 0 | 1 | 3 | 1 | 3 | |
| Counts did not recover within time frame to begin cycle 4 | 0 | 1 | 3 | 1 | 3 | |
| Other complicating disease | 1 | 3 | 1 | 3 | ||
Patient #6 terminated treatment because of low platelet count (grade 4) and infection (grade 3) possibly related to doxorubicin and cyclophosphamide. Patient #3 terminated treatment because of left hemiparesis (grade 3), possibly related to cytarabine and vincristine. Patient #1 terminated treatment because of confusion (grade 3) unrelated to treatment. Patient #27 terminated treatment because of grade 3 encephalopathy and grade 3 pneumonitis/pulmonary infiltrates. The encephalopathy was reported as possibly related to treatment. (This patient with pretreatment cirrhosis died 35 days later because of hepatic failure with contributing causes listed as hepatitis B, cirrhosis, pneumonia, and HIV, and death as a result of treatment toxicity was reported.) Patient #30 terminated treatment because of grade 4 neutropenia and grade 3 white blood cell count, which were probably/possibly related to treatment.